NANOBIOTIX Archives | Page 2 of 2

Home / Posts tagged NANOBIOTIX (Page 2)

Nanobiotix and MD Anderson Cancer Center Announce a Large-scale, Comprehensive Clinical Collaboration on NBTXR3

Paris, France, Cambridge, Massachusetts (USA) and Houston, Texas (USA), Jan. 7 (Korea Bizwire) – NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205) and The University of Texas MD Anderson Cancer Center today announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. [...]

Nanobiotix Revenues for the 3rd Quarter of 2018

Paris, France and Cambridge, Massachusetts, USA, Nov. 15 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its unaudited revenues for the third quarter of 2018. Income Statement for the third quarter of 2018 In € Q3 2018 Q2 2018 [...]

NANOBIOTIX: Positive Phase II/III Results for NBTXR3 in Soft Tissue Sarcoma Presented at ESMO

Paris, France, and Cambridge, Massachusetts (USA), Oct. 19 (Korea Bizwire) – NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, presented NBTXR3 positive Phase II/III Act.in.sarc results in patients with locally advanced Soft Tissue Sarcoma at the European Society for Medical Oncology (ESMO) 2018 Congress [...]

Nanobiotix Receives First Tranche Disbursement of 16 Million Euros Financing from European Investment Bank

Paris, France and Cambridge, Massachusetts, Oct. 16 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company received an initial 16 million euros as the first disbursement under the previously announced non-dilutive loan from the European Investment Bank [...]

Nanobiotix to Present Positive Results from its Phase II/III Clinical Trial of NBTXR3 in Patients with Soft Tissue Sarcoma (STS) and Other Ongoing Phase I/II Trials at Upcoming ESMO and ASTRO Annual Conferences

PARIS, France and CAMBRIDGE, Massachusetts, Sept. 26 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that detailed results of its phase II/III clinical trial of NBTXR3 in patients with soft tissue sarcoma (STS) will be presented by Dr. Sylvie Bonvalot, [...]

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other Program Data Presented at ImmunoRad 2018

PARIS / CAMBRIDGE, Mass., Sept. 20 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces it will present an update on and data from its NBTXR3 development program at the International Conference on Immunotherapy Radiotherapy Combinations that will take place from [...]